Evidence map›Paper›PMID 37074435›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia.

Lauren M Schwartz, Jennifer Oshinsky, Mardi Reymann, Mathew D Esona, Michael D Bowen, M Jahangir Hossain, Syed M A Zaman, Joquina Chiquita M Jones, Martin Antonio, Henry Badji and 23 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 9 institutions in 4 countries.

Lauren M SchwartzDepartment of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
Jennifer OshinskyCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mardi ReymannCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Mathew D EsonaDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Michael D BowenDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
M Jahangir HossainMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Syed M A ZamanMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Joquina Chiquita M JonesMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Martin AntonioMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Henry BadjiMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Golam SarwarMedical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Samba O SowCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Doh SanogoCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Adama Mamby KeitaCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Boubou TambouraCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Awa TraoréCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Uma OnwuchekwaCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Richard OmoreKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
Jennifer R VeraniDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Alex O AwuorKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
John B OchiengKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
Jane JumaKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
Billy OgwelKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
Umesh D ParasharDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jacqueline E TateDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Irene N KasumbaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Kathleen M NeuzilCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ali Rowhani-RahbarDepartment of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
M Elizabeth HalloranDepartment of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
Robert L AtmarDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Maryland, Baltimore · USCentre Pour le Développement des Vaccins-Mali · MLMRC Unit the Gambia · GMKenya Medical Research Institute · KECenters for Disease Control and Prevention · USUniversity of Washington · USBaylor College of Medicine · USCenters for Disease Control and Prevention · KEFred Hutch Cancer Center · US

Funding

Methods for Evaluating Vaccine EfficacyR37AI032042 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HALLORAN, M ELIZABETH · 2010 to 2019
$5.1M
Genetically determined susceptibility to rotavirus and rotavirus vaccine failure in sub-Saharan AfricaF31AI126629 · NIAID · UNIVERSITY OF WASHINGTON · PI SCHWARTZ, LAUREN MICHELLE · 2016 to 2017
$64k
NIAID NIH HHS F31 AI126629NIAID NIH HHS R37 AI032042
6 · The paper itself

Abstract

backgroundPreviously studied risk factors for rotavirus vaccine failure have not fully explained reduced rotavirus vaccine effectiveness in low-income settings. We assessed the relationship between histo-blood group antigen (HBGA) phenotypes and clinical rotavirus vaccine failure among children <2 years of age participating in the Vaccine Impact on Diarrhea in Africa Study in 3 sub-Saharan African countries.

methodsSaliva was collected and tested for HBGA phenotype in children who received rotavirus vaccine. The association between secretor and Lewis phenotypes and rotavirus vaccine failure was examined overall and by infecting rotavirus genotype using conditional logistic regression in 218 rotavirus-positive cases with moderate-to-severe diarrhea and 297 matched healthy controls.

resultsBoth nonsecretor and Lewis-negative phenotypes (null phenotypes) were associated with decreased rotavirus vaccine failure across all sites (matched odds ratio, 0.30 [95% confidence interval: 0.16-0.56] or 0.39 [0.25-0.62], respectively]. A similar decrease in risk against rotavirus vaccine failure among null HBGA phenotypes was observed for cases with P[8] and P[4] infection and their matched controls. While we found no statistically significant association between null HBGA phenotypes and vaccine failure among P[6] infections, the matched odds ratio point estimate for Lewis-negative individuals was >4.

conclusionsOur study demonstrated a significant relationship between null HBGA phenotypes and decreased rotavirus vaccine failure in a population with P[8] as the most common infecting genotype. Further studies are needed in populations with a large burden of P[6] rotavirus diarrhea to understand the role of host genetics in reduced rotavirus vaccine effectiveness.

Indexed as

Blood Group AntigensRotavirusRotavirus InfectionsRotavirus VaccinesDiarrheaGambiaHumansKenyaMaliPhenotypeBlood Group AntigensRotavirus VaccinesHBGA phenotypehost geneticsrotavirus vaccine failure

Identifiers

PMID37074435
PMCPMC10116560
OpenAlexW4366350995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.